<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>6551567</pmcid><all-ids><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="pmid">31174102</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="pmc">6551567</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="publisher-id">S2213-1582(19)30225-6</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="doi">10.1016/j.nicl.2019.101875</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="publisher-id">101875</article-id></all-ids><extracted-table><table-id>t0005</table-id><table-label>Table 1</table-label><table-caption>Narcolepsy patient demographics.</table-caption><original-table><table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" position="float" id="t0005"><label>Table 1</label><caption><p>Narcolepsy patient demographics.</p></caption><alt-text id="al0035">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Patient</th><th rowspan="2">Gender</th><th rowspan="2">Age (y)</th><th rowspan="2">Narcolepsy duration (y)</th><th>CSF-orexin (pg/ml)<hr/></th><th rowspan="2">Medications</th></tr><tr><th>&lt;130 pg/ml</th></tr></thead><tbody><tr><td>1</td><td>F</td><td>17</td><td>6</td><td>81</td><td>Methylphenidate, fluoxetine</td></tr><tr><td>2</td><td>M</td><td>17</td><td>5</td><td>&lt;10</td><td>Methylphenidate, sodium oxybate</td></tr><tr><td>3</td><td>F</td><td>18</td><td>5</td><td>&lt;10</td><td>Methylphenidate, modafinil, fluoxetine</td></tr><tr><td>4</td><td>F</td><td>19</td><td>4</td><td>79</td><td>None</td></tr><tr><td>5</td><td>M</td><td>14</td><td>9</td><td>&lt;10</td><td>Methylphenidate</td></tr><tr><td>6</td><td>M</td><td>19</td><td>4</td><td>49</td><td>Methylphenidate</td></tr><tr><td>7</td><td>F</td><td>20</td><td>5</td><td>Unknown</td><td>Methylphenidate, sertraline</td></tr><tr><td>8</td><td>F</td><td>19</td><td>4</td><td>18</td><td>None</td></tr><tr><td>9</td><td>F</td><td>16</td><td>4</td><td>130</td><td>Methylphenidate, fluoxetine, levothyroxine</td></tr><tr><td>10</td><td>F</td><td>19</td><td>5</td><td>Unknown</td><td>Modafinil</td></tr><tr><td>11</td><td>M</td><td>16</td><td>4</td><td>Unknown</td><td>Methylphenidate, fluoxetine</td></tr><tr><td>12</td><td>F</td><td>15</td><td>4</td><td>Unknown</td><td>Modafinil, fluoxetine</td></tr><tr><td>13</td><td>F</td><td>18</td><td>5</td><td>Unknown</td><td>Methylphenidate, fluoxetine</td></tr><tr><td>14</td><td>F</td><td>17</td><td>5</td><td>&lt;10</td><td>Methylphenidate, fluoxetine, zolpidem</td></tr></tbody></table></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Narcolepsy patient demographics.</div>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Patient</th><th rowspan="2">Gender</th><th rowspan="2">Age (y)</th><th rowspan="2">Narcolepsy duration (y)</th><th>CSF-orexin (pg/ml)</th><th rowspan="2">Medications</th></tr><tr><th>&lt;130 pg/ml</th></tr></thead><tbody><tr><td>1</td><td>F</td><td>17</td><td>6</td><td>81</td><td>Methylphenidate, fluoxetine</td></tr><tr><td>2</td><td>M</td><td>17</td><td>5</td><td>&lt;10</td><td>Methylphenidate, sodium oxybate</td></tr><tr><td>3</td><td>F</td><td>18</td><td>5</td><td>&lt;10</td><td>Methylphenidate, modafinil, fluoxetine</td></tr><tr><td>4</td><td>F</td><td>19</td><td>4</td><td>79</td><td>None</td></tr><tr><td>5</td><td>M</td><td>14</td><td>9</td><td>&lt;10</td><td>Methylphenidate</td></tr><tr><td>6</td><td>M</td><td>19</td><td>4</td><td>49</td><td>Methylphenidate</td></tr><tr><td>7</td><td>F</td><td>20</td><td>5</td><td>Unknown</td><td>Methylphenidate, sertraline</td></tr><tr><td>8</td><td>F</td><td>19</td><td>4</td><td>18</td><td>None</td></tr><tr><td>9</td><td>F</td><td>16</td><td>4</td><td>130</td><td>Methylphenidate, fluoxetine, levothyroxine</td></tr><tr><td>10</td><td>F</td><td>19</td><td>5</td><td>Unknown</td><td>Modafinil</td></tr><tr><td>11</td><td>M</td><td>16</td><td>4</td><td>Unknown</td><td>Methylphenidate, fluoxetine</td></tr><tr><td>12</td><td>F</td><td>15</td><td>4</td><td>Unknown</td><td>Modafinil, fluoxetine</td></tr><tr><td>13</td><td>F</td><td>18</td><td>5</td><td>Unknown</td><td>Methylphenidate, fluoxetine</td></tr><tr><td>14</td><td>F</td><td>17</td><td>5</td><td>&lt;10</td><td>Methylphenidate, fluoxetine, zolpidem</td></tr></tbody></table></div></transformed-table></extracted-table><extracted-table><table-id>t0010</table-id><table-label>Table 2</table-label><table-caption>Descriptive statistics of clinical data. The table shows mean values, standard deviations (sd), and two-tailed p-values from actigraphy measurements and questionnaires. The actigraphy data “Lying down”, “sleep duration”, and “sleep efficacy” refer to daily mean. Visual analogue scale (VAS) data for fatigue, depression, anxiety, and sleepiness were collected before MRI. ESS = Epworth sleepiness scale.</table-caption><original-table><table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" position="float" id="t0010"><label>Table 2</label><caption><p>Descriptive statistics of clinical data. The table shows mean values, standard deviations (sd), and two-tailed <italic>p</italic>-values from actigraphy measurements and questionnaires. The actigraphy data “Lying down”, “sleep duration”, and “sleep efficacy” refer to daily mean. Visual analogue scale (VAS) data for fatigue, depression, anxiety, and sleepiness were collected before MRI. ESS = Epworth sleepiness scale.</p></caption><alt-text id="al0040">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>Mean (sd) Narcolepsy</th><th>Mean (sd) Healthy controls</th><th>p-value</th></tr></thead><tbody><tr><td>Age (years)</td><td>16.4 (2.2)</td><td>16.7 (2.1)</td><td>0.745</td></tr><tr><td>Actigraphy duration (days)</td><td>6.0 (1.4)</td><td>6.0 (1.0)</td><td>1.000</td></tr><tr><td>Actigraphy duration (%)</td><td>90.7 (6.8)</td><td>91.2 (6.6)</td><td>0.827</td></tr><tr><td>Lying down, (hh:mm/24 h)</td><td>9:37 (2:17)</td><td>7:55 (0:51)</td><td><bold>0.012</bold></td></tr><tr><td>Sleep duration, (hh:mm/24 h)</td><td>6:00 (1:53)</td><td>6:29 (0:54)</td><td>0.361</td></tr><tr><td>Sleep efficacy (%)</td><td>63 (15)</td><td>82 (6)</td><td><bold>&lt;0.001</bold></td></tr><tr><td>ESS [0–24]</td><td>15.9 (3.3)</td><td>5.6 (3.5)</td><td><bold>&lt;0.001</bold></td></tr><tr><td>Cataplexy [0–35]</td><td>12.1 (7.1)</td><td>3.4 (3.1)</td><td><bold>&lt;0.001</bold></td></tr><tr><td>VAS Fatigue [0−100]</td><td>40.1 (21.8)</td><td>37.2 (23.8)</td><td>0.743</td></tr><tr><td>VAS Depression [0–100]</td><td>4.6 (8.2)</td><td>5.4 (4.8)</td><td>0.760</td></tr><tr><td>VAS Anxiety [0–100]</td><td>7.6 (10.4)</td><td>14.8 (20.2)</td><td>0.251</td></tr><tr><td>VAS Sleepiness [0–100]</td><td>33.1 (25.6)</td><td>34.6 (26.8)</td><td>0.881</td></tr></tbody></table><table-wrap-foot><fn><p>Significant differences between narcolepsy patients and healthy controls are marked with p-values in bold font.</p></fn></table-wrap-foot></table-wrap></original-table><transformed-table>Table 2<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Descriptive statistics of clinical data. The table shows mean values, standard deviations (sd), and two-tailed p-values from actigraphy measurements and questionnaires. The actigraphy data “Lying down”, “sleep duration”, and “sleep efficacy” refer to daily mean. Visual analogue scale (VAS) data for fatigue, depression, anxiety, and sleepiness were collected before MRI. ESS = Epworth sleepiness scale.</div>Table 2<div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>Mean (sd) Narcolepsy</th><th>Mean (sd) Healthy controls</th><th>p-value</th></tr></thead><tbody><tr><td>Age (years)</td><td>16.4 (2.2)</td><td>16.7 (2.1)</td><td>0.745</td></tr><tr><td>Actigraphy duration (days)</td><td>6.0 (1.4)</td><td>6.0 (1.0)</td><td>1.000</td></tr><tr><td>Actigraphy duration (%)</td><td>90.7 (6.8)</td><td>91.2 (6.6)</td><td>0.827</td></tr><tr><td>Lying down, (hh:mm/24 h)</td><td>9:37 (2:17)</td><td>7:55 (0:51)</td><td>0.012</td></tr><tr><td>Sleep duration, (hh:mm/24 h)</td><td>6:00 (1:53)</td><td>6:29 (0:54)</td><td>0.361</td></tr><tr><td>Sleep efficacy (%)</td><td>63 (15)</td><td>82 (6)</td><td>&lt;0.001</td></tr><tr><td>ESS [0–24]</td><td>15.9 (3.3)</td><td>5.6 (3.5)</td><td>&lt;0.001</td></tr><tr><td>Cataplexy [0–35]</td><td>12.1 (7.1)</td><td>3.4 (3.1)</td><td>&lt;0.001</td></tr><tr><td>VAS Fatigue [0−100]</td><td>40.1 (21.8)</td><td>37.2 (23.8)</td><td>0.743</td></tr><tr><td>VAS Depression [0–100]</td><td>4.6 (8.2)</td><td>5.4 (4.8)</td><td>0.760</td></tr><tr><td>VAS Anxiety [0–100]</td><td>7.6 (10.4)</td><td>14.8 (20.2)</td><td>0.251</td></tr><tr><td>VAS Sleepiness [0–100]</td><td>33.1 (25.6)</td><td>34.6 (26.8)</td><td>0.881</td></tr></tbody></table></div>Significant differences between narcolepsy patients and healthy controls are marked with p-values in bold font.</transformed-table></extracted-table></extracted-tables-set>